Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vertex Pharmaceuticals's other long-term assets for the quarter that ended in Jun. 2026 was MXN74,364 Mil.
Vertex Pharmaceuticals's quarterly other long-term assets
increased
from Dec. 2025 (MXN74,445 Mil) to Mar. 2026 (MXN75,813 Mil) but then
stayed the same
from Mar. 2026 (MXN75,813 Mil) to Jun. 2026 (MXN74,364 Mil).
Vertex Pharmaceuticals's annual other long-term assets
increased
from Dec. 2023 (MXN45,956 Mil) to Dec. 2024 (MXN69,458 Mil) and
increased
from Dec. 2024 (MXN69,458 Mil) to Dec. 2025 (MXN74,445 Mil).
Vertex Pharmaceuticals Other Long Term Assets Historical Data
* Premium members only.
The historical data trend for Vertex Pharmaceuticals's Other Long Term Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals Other Long Term Assets Chart
Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.
What does a Other Long Term Assets of MXN74,364 Mil mean?
Vertex Pharmaceuticals (MEX:VRTX) has a Other Long Term Assets of MXN74,364 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Other Long Term Assets too high?
Vertex Pharmaceuticals' current Other Long Term Assets is MXN74,364 Mil. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Other Long Term Assets compare to REGN and RVMD?
Vertex Pharmaceuticals' Other Long Term Assets of MXN74,364 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Other Long Term Assets is MXN74,364 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,828.26, compared to a current price of MXN8,176.21 — trading 7.4% below its estimated fair value. The current Other Long Term Assets is MXN74,364 Mil. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Other Long Term Assets is MXN74,364 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN8,176.21 is trading 7.4% below its estimated GF Value™ of MXN8,828.26.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
Other Long Term Assets: MXN74,364 Mil
GF Value™: MXN8,828.26 vs. price of MXN8,176.21 (7.4% below fair value)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score
Get the complete analysis for MEX:VRTX
Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
